<DOC>
	<DOCNO>NCT00147875</DOCNO>
	<brief_summary>The objective study assess feasibility efficacy combination chemotherapy ( PVAG ) elderly patient advance stage Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Study Prednisone , Vinblastine , Doxorubicin , Gemcitabine Elderly Patients With Advanced Stages Hodgkin 's Lymphoma</brief_title>
	<detailed_description>Gemcitabine show promising activity patient relapse lymphoma either administer single agent combination cytotoxic agent . No trial date evaluate role patient primary Hodgkin 's lymphoma . We therefore developed three-weekly regimen base standard ABVD regimen .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Hodgkin 's lymphoma ( histologically proven ) Clinical stage IIB ( risk factor bulky mediastinal mass and/or extranodal involvement ) , III , IV No prior antitumor therapy Age 60 75 year WHO performance status 02 Normal pulmonary function Written inform consent The following histology exclude : lymphocyte predominant HD Leukocytes &lt; 2,500/microL Platelets &lt; 100,000/microL</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Advanced stag Hodgkin 's lymphoma</keyword>
	<keyword>Elderly</keyword>
</DOC>